Regenxbio (RGNX) Cash & Current Investments (2014 - 2025)

Regenxbio's Cash & Current Investments history runs 12 years deep, the most recent figure standing at $230.1 million for Q4 2025.

• In Q4 2025, Cash & Current Investments fell 1.97% year-over-year to $230.1 million; the TTM figure through Dec 2025 stood at $230.1 million (down 1.97% YoY), while the FY2025 annual figure was $230.1 million, down 1.97% from the prior year.
• Cash & Current Investments was $230.1 million for Q4 2025 at Regenxbio, down from $274.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $457.4 million in Q4 2021 to a low of $230.1 million in Q4 2025.
• Historically, Cash & Current Investments has averaged $330.0 million across 5 years, with a median of $327.6 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Cash & Current Investments jumped 57.88% in 2021, then retreated 24.51% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $457.4 million in 2021, then fell by 20.29% to $364.6 million in 2022, then declined by 24.51% to $275.3 million in 2023, then slipped by 14.74% to $234.7 million in 2024, then decreased by 1.97% to $230.1 million in 2025.
• The last three Cash & Current Investments figures came in at $230.1 million (Q4 2025), $274.2 million (Q3 2025), and $323.3 million (Q2 2025), per Business Quant data.